Skip to main content

Table 2 Patient’s Demographics and Cancer Treatment Characteristics Based on Pre-operative Anemia Status

From: Pre-operative anemia and peri-operative transfusion are associated with poor oncologic outcomes in cancers of the esophagus: potential impact of patient blood management on cancer outcomes

 

Anemic (n = 216)

Not Anemic (n = 122)

p-value

Age*

68 ± 10 years

64 ± 10 years

0.001

Gender

37 (17%) Female

35 (29%) Female

0.018

179 (83%) Male

87 (71%) Male

Anemic at Diagnosis**

120/289 (42%)

113 (62%)

7 (7%)

0.0002

Clinical T Stage (N = 289)

1 13(7%)

2 17 (9%)

3 157 (83%)

4 2 (1%)

1 25 (25%)

2 20 (20%)

3 55 (55%)

4 0 (0%)

< 0.0001

Tumor Histology

33 (16%) Squamous

178 (84%) Adenoca

15 (12%) Squamous

106 (88%) Adenoca

0.52

Treated with NARx

166 (77%)

47 (39%)

< 0.0001

Diagnosis to OR (days)*,$

148 ± 539 days

130 ± 39 days

0.01

Complete Response (CR) to NARx$

57 (34%)

19 (40%)

0.49

Estimated Blood Loss (EBL)*

280 ± 180 ml

289 ± 215 ml

0.72

Pathologic/Surgical T Stage

0 59 (27%)

1 36 (17%)

2 42 (20%)

0 75 (36%)

1 2 (1%)

In-Situ 1 (< 1%)

0 21 (17%)

1 46 (38%)

2 18 (15%)

0 34 (28%)

1 0 (0%)

In-Situ 3 (2%)

0.0002

Lymph Node Status

138 (64%) Negative

78 (64%) Negative

1.00

77 (36%) Positive

44 (36%) Positive

Hospital Length of Stay *

11 ± 11 days

11 ± 11 days

0.66

  1. * Mean + S.D. reported
  2. ** anemia diagnosed as Hb < 12.0 g/dL for women and Hb < 13.5 g/dL for men
  3. $ for cases treated with neoadjuvant chemo/radiotherapy only